Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update-Reference-Cited by-同舟云学术

Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update

Published:2018-05 Issue: Volume:94 Page:115-125
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Choueiri Toni K.,Hessel Colin,Halabi Susan,Sanford Ben,Michaelson M. Dror,Hahn Olwen,Walsh Meghara,Olencki Thomas,Picus Joel,Small Eric J.,Dakhil Shaker,Feldman Darren R.,Mangeshkar Milan,Scheffold Christian,George Daniel,Morris Michael J.

Funder

National Institutes of Health

Exelixis, Inc

Dana-Farber/Harvard Cancer Center Kidney SPORE and Program

Kohlberg Chair at Harvard Medical School and the Trust Family

Loker Pinard Funds for Kidney Cancer Research

Memorial Sloan Kettering Cancer Center

Exelixis

Publisher

Elsevier BV

Subject

Cancer Research,Oncology